Q32 Bio restructures to focus on bempikibart; discontinues ADX-097 renal trial, cuts workforce

Q32 Bio Inc.

Restructuring prioritizes bempikibart for alopecia areata; discontinues Phase 2 renal basket trial for ADX-097.
Expects $1.1M severance charges; cash runway extended to second half of 2026.
Open-label extension for SIGNAL-AA Part A initiates in 1H'25; Part B dosing starts 1H'25 with topline data expected 1H'26.
Evaluating strategic options for tissue-targeted complement inhibitor platform, including ADX-097 and early-stage assets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.